• Hydroxytyrosol N2302 for Reliable Cell Assays

  2026-09-10

  This scenario-driven guide explains how Hydroxytyrosol (SKU N2302) can be incorporated into cell viability, proliferation, cytotoxicity, and oxidative-stress workflows without confusing antioxidant activity with cell survival. It combines formulation data, assay controls, protocol starting points, interpretation safeguards, and practical vendor-selection criteria for biomedical laboratories.

• Obeticholic Acid Workflows for FXR Liver Research

  2026-09-10

  Obeticholic Acid provides a receptor-proximal way to connect FXR activation with bile acid transport, metabolic signaling, and fibrosis-related phenotypes. This practical guide translates a recent 11β-HSD1 liver fibrosis study into complementary hepatocyte, immune, and in vivo workflows while emphasizing controls and troubleshooting.

• Olsalazine Sodium: From Chemotaxis to Translation

  2026-09-09

  A translational perspective on Olsalazine Sodium as a mesalamine dimer, anti-inflammatory prodrug, and research tool spanning LTB4 chemotaxis, colorectal cancer tumor models, and xenobiotic transport studies.

• Prochlorperazine Hemidystonia as a Stroke Mimic

  2026-09-09

  The reference case shows how prochlorperazine-induced hemidystonia can closely resemble acute ischemic stroke, especially when unilateral weakness and dysarthria trigger an emergency stroke response. Its practical contribution is a medication-centered, serial examination strategy that helps clinicians identify a reversible stroke mimic without delaying appropriate neuroimaging or safety assessment.

• Rimonabant (SR141716): A Translational CB1 Lens

  2026-09-08

  Rimonabant (SR141716) is more than a historical appetite-focused compound: it is a selective CB1 pharmacology tool for separating endocannabinoid signaling from emerging non-cannabinoid mechanisms. By pairing CB1 antagonism with the A2A-dependent terpene findings reported in chronic pain research, translational teams can design sharper experiments across appetite, inflammation, neurobiology, and pain.

• Isoliensinine, TRPV1–AMPK in MAFLD Fibrosis

  2026-09-08

  A 2025 Journal of Future Foods study identifies a TRPV1–AMPK/ACC–lipid droplet axis through which isoliensinine reduces hepatic stellate cell activation and fibrosis in MAFLD models. Its combination of dietary and chemical in vivo models with LX2-cell mechanistic experiments provides a framework for testing lipid droplet restoration as an anti-fibrotic strategy, while leaving human translation and pathway specificity for further study.

• Chloroquine BA1002: Practical Research Workflow

  2026-09-07

  Chloroquine (BA1002) provides a solvent-aware, assay-focused approach for investigating lysosomal function, autophagy-related readouts, inflammatory signaling, and selected cancer or antiviral models. It should be treated as a pleiotropic research compound rather than a selective pathway probe or clinical dosing substitute, particularly when no directly matched paper evidence is available.

• Chloroquine as a Probe of Itch–Pain Circuits

  2026-09-07

  Chloroquine is more than an autophagy inhibitor: its activity at MrgprA3+ sensory neurons creates a valuable framework for separating itch, pain, inflammation, and cellular stress in translational assays.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-09-05

  The reference study identifies TBXA2R as a GPCR that activates ezrin, radixin, and moesin through Gαq/11, Gα12/13, Rho GTPases, and the SLK/LOK kinase module. This signaling axis links receptor activity to triple-negative breast cancer motility, invasion, and metastatic colonization, providing a mechanistic framework for studying GPCR-driven cytoskeletal plasticity.

• Demethyleneberberine: Assay Design and Mechanism

  2026-09-04

  Demethyleneberberine (DMB) is a mechanism-rich natural alkaloid for NSCLC and inflammatory disease research. This guide focuses on choosing orthogonal assays that distinguish cytostasis, senescence, and anti-inflammatory activity while preserving model-specific interpretation.

• Deracoxib and Piroxicam in Canine Osteosarcoma

  2026-09-04

  The reference study compared Deracoxib and piroxicam directly in three canine osteosarcoma cell lines and a fibroblast model, showing stronger and more consistent growth inhibition with Deracoxib. Its findings support selective in vitro cytotoxicity at intermediate-to-high concentrations, but the absence of DNA fragmentation and limited apoptosis testing argue against assuming a specific cell-death mechanism.

• PDK4 Inhibitors for Metabolic Disease: Study Insights

  2026-09-03

  This 2019 Journal of Medicinal Chemistry study used anthraquinone-based medicinal chemistry and allosteric-site modeling to identify compound 8c as a potent PDK4 inhibitor. The lead combined cellular and biochemical activity with metabolic, allergy, and cancer-related efficacy signals, while its stability and pharmacokinetic characterization supported further preclinical investigation.

• WY-14643 for PPARα and Metabolic Research

  2026-09-03

  WY-14643 (Pirinixic Acid) provides a direct pharmacologic handle for testing PPARα-dependent lipid metabolism, inflammation, and insulin sensitivity enhancement. Its use alongside multiomics and tumor-microenvironment assays can help distinguish receptor-driven effects from broader activity of endogenous fatty acids.

• Chloroquine BA1002: Mechanism and Research Uses

  2026-09-02

  Chloroquine is a 4-aminoquinoline and an autophagy inhibitor for research that primarily disrupts lysosomal acidification and late autophagic flux. BA1002 is therefore useful for studying malaria, rheumatoid arthritis, immune signaling, viral entry, and cancer-cell stress, but in vitro activity does not establish clinical efficacy.

• Urolithin A for Mitochondrial Quality Control

  2026-09-02

  Urolithin A provides a practical way to connect mitophagy, mitochondrial respiration, inflammation, and metabolic remodeling in cell-based studies. This guide combines product-specific handling with a fibrosis-focused assay strategy inspired by the SIRT4–GDH findings in hepatic stellate cells.

7827 records 1/522 page Next 12345 下5页 Last page